Potential Biomarkers of the Severity of Endothelial Damage in End-stage Chronic Kidney Failure (DIALYSOX)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The principal objective of this study is to qualify markers of oxidative stress in inflammatory cells (monocytes) in patients with stage 3 kidney failure (diabetic or not), and patients with end-stage kidney failure (diabetic or not), who require dialysis. The evaluation of these markers will be done by the activation and localization of proteins implicated in vascular tone and oxidative stress in monocytes, correlated with the distribution of cholesterol sphingomyelin within planar rafts and caveolae. The aim is to describe their evolution under treatment, which could lead to interventional studies.
Activation of 5 proteins relocated in the membrane of monocytes (eNOS, iNOS, gp91phox and receptors of angiotensin II (AT1 and AT2)) within dynamic lipid structures, rafts, measured by western blot-dot blot. [ Time Frame: at the beginning of the period Day 0, at 1 month and at 3 months. ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient who have been informed about the research
Patients with national health insurance cover
Patients aged between 18 and 75 years
Patients with stage 3 kidney failure (30 ml/min < cl creat < 59 ml/min) diabetic or not
Patients with stage 5 kidney failure (cl creat < 15 ml/mn) diabetic or not and requiring dialysis.
Patients under guardianship
Pregnant or breast-feeding women
Infection (including peritonitis in peritoneal dialysis, infection of the catheter insertion site),
Systemic diseases in flare,
Patients positive for Human Immunodeficience Virus (HIV),
Patients on immunosuppressants
Patients taking antioxidants (selenium, vitamin C and/or E)